Likvor has increased the staff with two new employees. Now they are six in total.

2012 meeting of the International Society of Hydrocephalus and CSF Disorders (ISHCSF), will be held in Kyoto from October 19 to 22, 2012 (Hydrocephalus 2012, Kyoto). http://www.ishcsf2012.jp/index.html

An ownership group consisting of Uminova Invest, PartnerInvest and former CEO Kjell Öberg acquires Allenex' holdings in Likvor to strengthen the company's ownership structure. The medtech-company Likvor AB manufactures and sells the unique Likvor CELDA^® System which can identify a way back to normalized life for millions of dementia patients with the condition NPH, also known as treatable dementia.

The medtech company Likvor AB strengthens its competences with a new chairman of the board, Stefan Sallerfors. Sallerfors has a background as doctor and specialist in medical radiology and has been CEO for GE Medical System Sverige AB and Helsingborg hospital. In November Likvor continues the expansion on the European market with a new distribution agreement for the German market. The unique Likvor CELDA^® System is therefore available in Germany, Austria and Switzerland through the new distributor, Neuromed. The system helps to restore normal life back to millions of dementia patients with hydrocephalus diagnosis.

The unique Likvor CELDA^® System is now available on the UK market and the first system has been sent to a customer. In addition, Likvor AB has signed a distribution agreement with its first distributor for this region. The system helps to restore normal life back to millions of dementia patients with hydrocephalus diagnosis.

Likvor will appear at the 2011 meeting of the International Society for Hydrocephalus and CSF Disorders in Copenhagen. Likvor will be demonstrating the Likvor CELDA^® System and answering any questions regarding the product. Likvor is at present focusing on expanding the international and global sales network with potential business partners for the Likvor CELDA^® System.

Likvor AB moves towards the international market for treatable dementia with a new CEO and a fresh injection of capital.

Likvor AB is pleased to announce the appointment of Dr. Hadi Ghane, as Sales Director for our team. As "Sales Director", Dr. Ghane will be responsible for the sales activities of Likvor's current product portfolio, Likvor CELDA^® System. Dr. Ghane will be a valuable contributor to and be an active part in the team to build up and prepare the company for future growth and expansion.